Is irritable bowel syndrome an inflammatory disorder?

被引：59

作者：

Giorgio R. ^{[1
]}

Barbara G. ^{[1
]}

机构：

[1] Department of Internal Medicine and Gastroenterology, St. Orsola-Malpighi Hospital, Bologna I-40138

来源：

Current Gastroenterology Reports | 2008年 / 10卷 / 4期

关键词：

Mast Cell; Irritable Bowel Syndrome; Food Allergy; Irritable Bowel Syndrome Patient; Irritable Bowel Syndrome Symptom;

D O I：

10.1007/s11894-008-0073-0

中图分类号：

学科分类号：

摘要：

Histopathologic data demonstrate low-grade mucosal inflammation in a subset of patients with irritable bowel syndrome (IBS). This inflammatory infiltrate is mainly represented by increased numbers of T lymphocytes and mast cells lying in the lamina propria. The close apposition of immunocytes to gut nerves supplying the mucosa provides a basis for neuroimmune cross-talk, which may explain gut sensorimotor dysfunction and related symptoms in patients with IBS. A previous gastroenteritis (due to Campylobacter jejuni, Salmonella, Shigella, Escherichia coli, and, likely, viruses) is now an established etiologic factor for IBS (hence, postinfectious IBS). Other putative causes, such as undiagnosed food allergies, genetic abnormalities, stress, or bile acid malabsorption, may also promote and maintain a low-grade mucosal inflammation in IBS. The identification of mucosal inflammation in IBS has pathophysiologic implications and paves the way for novel therapeutic options. © Springer Science+Business Media, LLC 2008.

引用

页码：385 / 390

页数：5

共 50 条

[1]

Collins S.M., The immunomodulation of enteric neuromuscular function: Implications for motility and inflammatory disorders, Gastroenterology, 111, pp. 1683-1699, (1996)

[2]

Barbara G., De Giorgio R., Stanghellini V., Et al., A role for inflammation in irritable bowel syndrome?, Gut, 51, SUPPL. 1, (2002)

[3]

Camilleri M., Management of the irritable bowel syndrome, Gastroenterology, 120, pp. 652-668, (2001)

[4]

De Giorgio R., Barbara G., Stanghellini V., Et al., Diagnosis and therapy of irritable bowel syndrome, Aliment Pharmacol Ther, 20, SUPPL. 2, pp. 10-22, (2004)

[5]

Longstreth G.F., Hawkey C.J., Mayer E.A., Et al., Characteristics of patients with irritable bowel syndrome recruited from three sources: Implications for clinical trials, Aliment Pharmacol Ther, 15, pp. 959-964, (2001)

[6]

Longstreth G.F., Thompson G.W., Chey W.D., Et al., Functional bowel disorders, Gastroenterology, 130, pp. 1480-1491, (2006)

[7]

Barbara G., De Giorgio R., Stanghellini V., Et al., New pathophysiological mechanisms in irritable bowel syndrome, Aliment Pharmacol Ther, 20, pp. 1-9, (2004)

[8]

Isgar B., Harman M., Kaye M.D., Whorwell P.J., Symptoms of irritable bowel syndrome in ulcerative colitis in remission, Gut, 24, pp. 190-192, (1983)

[9]

Spiller R.C., Postinfectious irritable bowel syndrome, Gastroenterology, 124, pp. 1662-1671, (2003)

[10]

Barbara G., Vallance B.A., Collins S.M., Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice, Gastroenterology, 113, pp. 1224-1232, (1997)

← 1 2 3 4 5 →